首页> 外文期刊>Hepatitis Monthly >PREDICTION OF HEPATITIS B VIRUS LAMIVUDINE RESISTANCE BASED ON YMDD SEQUENCE DATA USING AN ARTIFICIAL NEURAL NETWORK MODEL
【24h】

PREDICTION OF HEPATITIS B VIRUS LAMIVUDINE RESISTANCE BASED ON YMDD SEQUENCE DATA USING AN ARTIFICIAL NEURAL NETWORK MODEL

机译:基于YMDD序列数据的人工神经网络模型预测乙型肝炎病毒拉米夫定的耐药性

获取原文
       

摘要

Background: Hepatitis B virus (HBV) infection is an important health problem worldwide with critical outcomes. The nucleoside analog lamivudine (LMV) is a potent inhibitor of HBV polymer-ase and impedes HBV replication in patients with chronic hepatitis B. Treatment with LMV for long periods causes the appearance and reproduction of drug-resistant strains, rising to more than 40% after 2 years and to over 50% and 70% after 3 and 4 years, respectively.Objectives: Artificial neural networks (ANNs) were used to make predictions with regard to re-sistance phenotypes using biochemical and biophysical features of the YMDD sequence.Patients and Methods: The study population comprised patients who were intended for surgery in various hospitals in Tehran-Iran. An ACRS-PCR method was performed to distinguish muta-tions in the YMDD motif of HBV polymerase. In the training and testing stages, these parameters were used to identify the most promising optimal network. The ideal values of RMSE and MAE are zero, and a value near zero indicates better performance. The selection was performed using statistical accuracy measures, such as root mean square error (RMSE), coefficient of determina-tion (R2), and mean absolute error (MAE). The main purpose of this paper was to develop a new method based on ANNs to simulate HBV drug resistance using the physiochemical properties of the YMDD motif and compare its results with multiple regression models.Results: The results of the MLP in the training stage were 0.8834, 0.07, and 0.09 and 0.8465, 0.160.04 in the testing stage; for the total data, the values were 0.8549, 0.115, and 0.065, respec-tively. The MLP model predicts lamivudine resistance in HBV better than the MLR model. Conclusions: The ANN model can be used as an alternative method of predicting the outcome of HBV therapy. In a case study, the proposed model showed vigorous clusterization of predicted and observed drug responses. The current study was designed to develop an algorithm for pre-dicting drug resistance using chemiophysical data with artificially created neural networks. To this end, an intelligent and multidisciplinary program should be developed on the basis of the information to be gained on the essentials of different applications by similar investigations. This program will help design expert neural network architectures for each application auto-matically.
机译:背景:乙型肝炎病毒(HBV)感染是全球范围内重要的健康问题,并具有关键的后果。核苷类似物拉米夫定(LMV)是一种有效的HBV聚合酶抑制剂,可抑制慢性乙型肝炎患者的HBV复制。长期服用LMV会导致耐药菌株的出现和繁殖,上升至40%以上目的:使用人工神经网络(ANN)根据YMDD序列的生化和生物物理特征对耐药表型进行预测。方法:研究人群包括打算在德黑兰-伊朗各医院进行手术的患者。进行了ACRS-PCR方法以区分HBV聚合酶YMDD基序中的突变。在训练和测试阶段,这些参数用于确定最有希望的最佳网络。 RMSE和MAE的理想值为零,接近零的值表示更好的性能。选择使用统计精度度量进行,例如均方根误差(RMSE),确定系数(R2)和平均绝对误差(MAE)。本文的主要目的是开发一种基于ANN的新方法,利用YMDD基序的理化特性模拟HBV耐药性,并将其结果与多元回归模型进行比较。结果:训练阶段的MLP结果为0.8834在测试阶段分别为0.07和0.09、0.89和0.8465、0.160.04;对于总数据,值分别为0.8549、0.115和0.065。 MLP模型预测的HBV拉米夫定耐药性优于MLR模型。结论:ANN模型可作为预测HBV治疗结果的替代方法。在一个案例研究中,提出的模型显示了预测和观察到的药物反应的强烈聚类。当前的研究旨在开发一种利用化学物理数据和人工创建的神经网络预测耐药性的算法。为此,应该根据通过类似研究从不同应用的本质中获得的信息来开发一个智能的多学科程序。该程序将帮助自动为每个应用程序设计专家神经网络体系结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号